A case of acute leukaemia with Ph1-chromosome and monosomy 7 is reported, in which the peripheral blood contained three types of blast cell as distinguished by light and electron microscopy and immunological phenotyping. The first blast-cell type originated from the granulocytic lineage; the cells contained per-oxidase-positive granules, and had an HLA-DR+Tdt-CALLA-phenotype. The second blast-cell type was more difficult to define, but had many characteristics of the monocytic series. The phenotype of these blast cells was HLA-DR+Tdt-CALLA-BA-2+ or HLA-DR+/–TA-1+63D3+. Finally, the third type of blast cell was clearly of lymphocytic origin. These cells were peroxidase-negative, and were CALLA+ as studied by electron microscopy using immunogold labelling and fluorescence microscopy. Their phenotype was HLA-DR+Tdt+CALLA+. Cell sorting and double fluorescence assays showed that these three populations were separate; no cells of mixed myeloid/lymphoid phenotype were found.This case suggests the neoplastic transformation of an immature progenitor cell and subsequent differentiation of the neoplastic cells in various directions.

Keywords:
Acute leukaemia, Cell markers, Cell sorter, Immunogold, Monosomy 7, Philadelphia chromosome, Progenitor cell
This content is only available via PDF.
© 1985 S. Karger AG, Basel
1985
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.